Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1200/JCO.2016.70.0872 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The prognosis and treatment consideration for non-small cell lung carcinoma patients with tumor size of >2.0-3.0 cm and visceral pleural invasion: a SEER-based study.
Transl Cancer Res
November 2024
Department of Thoracic Surgery, The First Affiliated Hospital of Shantou University Medical College, Shantou, China.
Background: Lung cancer is the most prevailing oncological disease worldwide. Visceral pleural invasion (VPI) has been proven to be a poor prognosis factor for early-stage non-small cell lung carcinoma (NSCLC) patients. However, there remains some debate regarding whether NSCLC patients with tumor size (TS) ranging from >2.
View Article and Find Full Text PDF[Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2024 edition)].
Zhonghua Yi Xue Za Zhi
September 2024
To further standardize lung cancer prevention and treatment measures in China, enhance the quality of diagnosis and treatment, improve patient prognosis, and provide evidence-based medical guidance for clinicians at all levels, the Chinese Medical Association convened experts from respiratory medicine, oncology, thoracic surgery, radiotherapy, imaging, and pathology to develop the Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2024 edition). This consensus resulted in several updates from the 2023 edition. The 2024 guidelines highlight that the risk of lung cancer in smokers remains higher than that of non-smokers even 15 years after quitting.
View Article and Find Full Text PDF[Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2024 edition)].
Zhonghua Zhong Liu Za Zhi
September 2024
To further standardize lung cancer prevention and treatment measures in China, enhance the quality of diagnosis and treatment, improve patient prognosis, and provide evidence-based medical guidance for clinicians at all levels, the Chinese Medical Association convened experts from respiratory medicine, oncology, thoracic surgery, radiotherapy, imaging, and pathology to develop the Chinese Medical Association's Clinical Diagnosis and Treatment Guidelines for Lung Cancer (2024 edition). This consensus resulted in several updates from the 2023 version. The 2024 guidelines highlight that the risk of lung cancer in smokers remains higher than that of non-smokers even 15 years after quitting.
View Article and Find Full Text PDFBibliometric analysis of the top 100 highly cited articles on sublobectomy for non-small cell lung cancer.
J Cardiothorac Surg
June 2024
Department of Thoracic Surgery, Peking Union Medical College Hospital, Shuaifuyuan 1, Wangfujing Street, Dongcheng District, Beijing, P. R. China.
Objectives: The goal of this research is to pinpoint the top 100 most frequently referenced studies on sublobectomy for non-small cell lung cancer.
Methods: We identified the top 100 most frequently referenced studies on sublobectomy for non-small cell lung cancer by searching the Web of Science database. We extracted key information from the selected studies, including the author, journal, impact factor, type of article, year of publication, country, organization, and keyword.
Long-term outcomes of lobectomy vs . sublobectomy for stage I lung invasive mucinous adenocarcinoma.
Chin Med J (Engl)
August 2024
Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!